EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

about

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q54222458

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@en

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@nl

type

Item

label

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@en

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@nl

prefLabel

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@en

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@nl

P1476

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

@en

P2093

Chenghui Li

http://www.w3.org/2001/XMLSchema#string

Fajun Xie

http://www.w3.org/2001/XMLSchema#string

Hong-Yang Lu

http://www.w3.org/2001/XMLSchema#string

Jing Qin

http://www.w3.org/2001/XMLSchema#string

Lei Lei

http://www.w3.org/2001/XMLSchema#string

Na Han

http://www.w3.org/2001/XMLSchema#string

P2860

Small cell lung cancer (SCLC): no treatment advances in recent years

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

The functions and regulation of the PTEN tumour suppressor

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

PTEN is a potent suppressor of small cell lung cancer.

P304

2217-2226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S159612

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29720878

http://www.w3.org/2001/XMLSchema#string

P932

5916454

http://www.w3.org/2001/XMLSchema#string